CARBAGLU 200 MG
CARGLUMIC ACID : 200 MG · DIN 02439360 · RECORDATI RARE DISEASES
Health Canada status: MARKETED
What is CARBAGLU?
CARBAGLU 200 MG contains CARGLUMIC ACID : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02439360, held by RECORDATI RARE DISEASES, supplied as TABLET FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Mar-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CARBAGLU used for?
Adjunctive therapy for acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, and acute hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02439360 |
|---|---|
| Brand name | CARBAGLU |
| Generic / active ingredient | CARGLUMIC ACID : 200 MG |
| Manufacturer | RECORDATI RARE DISEASES |
| Strength | 200 MG |
| Dosage form | TABLET FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A16AA05 CARGLUMIC ACID |
| AHFS class | 72:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Mar-2020 |
| Original market date | 2019-09-13 00:00:00 |
How is it administered?
NAGS: 100-250 mg/kg/day (acute), 10-100 mg/kg/day (maintenance). PA/MMA: 150 mg/kg/day for up to 7 days. Administer in 2-4 divided doses before meals. Disperse tablets in water; do not swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (refer to section 11), but typically requires specific conditions.
How is it supplied?
High density polyethylene bottles of 5 and 60 tablets with child resistant caps and desiccant.
Contraindications
Hypersensitivity to carglumic acid or any ingredient in the formulation. Contraindicated during breastfeeding.
Warnings and precautions
Acute hyperammonemia is a life-threatening emergency. Monitor plasma ammonia, neurological status, and renal function. Risk of brain injury or death if uncontrolled.
Who else supplies CARGLUMIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CARGLUMIC ACID appears in 23 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.